Miscellaneous: CUP: favourable subset (peritoneal)
Free question published 16 November 2026
A 64-year-old woman presents with abdominal distension. Imaging shows peritoneal carcinomatosis and ascites with no identifiable primary on CT of the chest, abdomen and pelvis. Cytology of the ascitic fluid shows adenocarcinoma. What is the most appropriate investigation and management pathway?
- AProceed directly to empirical single-agent gemcitabine
- BRefer to a head and neck MDT for examination under anaesthesia
- CCommence best supportive care without further site-specific investigation
- DRefer to a breast MDT for occult breast primary work-up
- EMeasure serum CA125 and manage along an ovarian/peritoneal cancer pathway
Why E is correct
Peritoneal adenocarcinoma with ascites in a woman is a recognised favourable CUP subset. NICE CG104 recommends measuring serum CA125 in women with peritoneal malignancy or ascites and managing them along an ovarian/peritoneal cancer pathway, because a presumed primary peritoneal or occult ovarian carcinoma is potentially platinum-responsive and carries a better prognosis than the general CUP population.
And why the others are not
- AEmpirical gemcitabine bypasses the recommended ovarian/peritoneal pathway for this favourable subset.
- BHead and neck referral is for cervical squamous nodal disease, not peritoneal adenocarcinoma.
- CBest supportive care prematurely abandons a potentially treatable favourable subset.
- DBreast MDT referral applies to axillary nodal adenocarcinoma, not peritoneal disease.
Source NICE CG104 - Metastatic malignant disease of unknown primary origin in adults — National Institute for Health and Care Excellence. Metastatic malignant disease of unknown primary origin in adults: diagnosis and management. NICE guideline CG104. Published July 2010, last updated 2023.
More free miscellaneous questions
- Miscellaneous: Neuroendocrine tumour: WHO grading · 05 November 2026
- Miscellaneous: Bone sarcoma: osteosarcoma chemotherapy · 25 October 2026
- Miscellaneous: Bone sarcoma: Ewing chemotherapy (Euro Ewing 2012) · 14 October 2026
Sitting in February? Follow the twenty-week plan.
2,500+ cited questions like this one are waiting in the vault.
See plans and pricing